Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1138979

registered interest
date	15/07/2019
answering body	Church Commissioners
answering dept id	9
answering dept short name	Church Commissioners
answering dept sort name	Church Commissioners
hansard heading	Churches: Equality
house id	1
legislature	25259 pref label House of Commons
question text	To ask the right hon. Member for Meriden, representing the Church Commissioners, what discussions the (a) Church of England and (b) Church in Wales have had with (i) other religious and faith bodies, (ii) the Government and (iii) the Equality and Human Rights Commission on the exemption of those bodies from equality legislation for appointments and provision of services.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	277265
answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>The Equality Act 2010 contains provisions that allow religious organisations to apply a limited range of religious occupational requirements to comply with the doctrines of the religion or to avoid conflicting with the strongly held religious beliefs of a significant number of the religion’s followers. The ability to apply religious occupational requirements arises where the employment is “for the purposes of an organised religion” and is not specific to the Church of England.</p><p>The Church of England has regular discussions with other religious and faith bodies, with HM Government, and with the Equality and Human Rights Commission on matters of mutual interest. From time to time these will include reflections on the importance for religious freedom of the provisions that protect faith and belief in the Equality Act.</p> answering member constituency Meriden answering member printed Dame Caroline Spelman question first answered 18/07/2019 10:47:39 answering member 312 label Biography information for Dame Caroline Spelman previous answer version 129637 answering member constituency Meriden answering member printed Dame Caroline Spelman answering member 312 label Biography information for Dame Caroline Spelman
tabling member	4623 label Biography information for Tonia Antoniazzi

1133166

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	266861
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:42:09 answering member 4455 label Biography information for Seema Kennedy
tabling member	4623 label Biography information for Tonia Antoniazzi

1133167

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	266862
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.</p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.</p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:43:17 answering member 4455 label Biography information for Seema Kennedy
tabling member	4623 label Biography information for Tonia Antoniazzi

1132764

registered interest
date	18/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	What progress the Government has made on making medical cannabis available to people who need it.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	911421
answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The Government acted swiftly to change the law and those patients for whom it is clinically appropriate can be prescribed medicinal cannabis. It is a clinical decision whether to prescribe, and prescriptions of medicinal cannabis are available, and being issued where it is judged clinically appropriate for the patient.</p><p /><p /> answering member constituency West Suffolk answering member printed Matt Hancock question first answered 18/06/2019 16:50:49 answering member 4070 label Biography information for Matt Hancock
tabling member	4623 label Biography information for Tonia Antoniazzi